Granted Patent B2

US 12,285,425 · App. 18/136,210 · Granted Apr 29, 2025

Inventor: Hazel Hunt (Storrington, GB)

Assignee: Corcept Therapeutics, Inc.

A61K31/4745A61K31/337A61P35/00

Abstract

Claims (42)

1. A method of treating a subject hosting a cervical cancer tumor, the method comprising administering to the subject an effective amount of a chemotherapeutic agent and an effective amount of non-steroidal selective glucocorticoid receptor modulator (SGRM) to reduce the tumor load of the cervical cancer tumor, wherein the SGRM is a fused azadecalin compound which has the formula:

wherein

L 1 and L 2 are members independently selected from a bond and unsubstituted alkylene;

R 1 is a member selected from unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted heterocycloalkyl, —OR 1A NR 1C R 1D , —C(O)NR 1C R 1D and —C(O)OR 1A , wherein

R 1A is a member selected from hydrogen, unsubstituted alkyl and unsubstituted heteroalkyl,

R 1C and R 1D are members independently selected from unsubstituted alkyl and unsubstituted heteroalkyl,

wherein R 1C and R 1D are optionally joined to form an unsubstituted ring with the nitrogen to which they are attached, wherein said ring optionally comprises an additional ring nitrogen;

R 2 has the formula:

wherein

R 2G is a member selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, —CN, and —CF 3 ;

J is phenyl;

t is an integer from 0 to 5;

X is —S(O 2 )—; and

R 5A is phenyl optionally substituted with 1-5 R 5A groups, wherein

R 5A is a member selected from hydrogen, halogen, —OR 5A1 , S(O 2 )NR 5A2 R 5A3 , —CN, and unsubstituted alkyl, wherein

R 5A1 is a member selected from hydrogen and unsubstituted alkyl, and

R 5A2 and R 5A3 are members independently selected from hydrogen and unsubstituted alkyl,

and salts thereof,

wherein said chemotherapeutic agent is an antimicrotubule agent.

2. The method of claim 1 , wherein the antimicrotubule agent is selected from the group consisting of vinca alkaloids, taxanes, and combinations thereof.

3. The method of claim 2 , wherein the antimicrotubule agent is a taxane.

4. The method of claim 3 , wherein the antimicrotubule agent is selected from the group consisting of docetaxel, paclitaxel, nab-paclitaxel, docosahexaenoic acid bound-paclitaxel, polyglutamate bound-paclitaxel, paclitaxel-EC-1, ANG105, and glucose-conjugated paclitaxel.

5. The method of claim 1 , wherein the antimicrotubule agent is a vinca alkaloid.

6. The method of claim 1 , wherein the antimicrotubule agent is selected from the group consisting of vincristine, vinblastine, vindesine, vinorelbine and vinorelbine tartrate, and combinations thereof.

7. The method of claim 1 , wherein the SGRM is:

8. A method of treating a subject hosting a cervical cancer tumor, the method comprising administering to the subject an effective amount of a chemotherapeutic agent and an effective amount of non-steroidal selective glucocorticoid receptor modulator (SGRM) to reduce the tumor load of the cervical cancer tumor, wherein the SGRM is an octahydro fused azadecalin compound which has the formula:

wherein

R 1 is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from R 1a ;

each R 1a is independently selected from the group consisting of hydrogen, C 1-6 alkyl, halogen, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, N-oxide, and C 3-8 cycloalkyl;

ring J is selected from the group consisting of an aryl ring and a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;

each R 2 is independently selected from the group consisting of hydrogen, C 1-6 alkyl, halogen, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkyl-C 1-6 alkoxy, CN, OH, NR 2a R 2b , C(O)R 2a , C(O)OR 2a , C(O)NR 2a R 2b , SR 2a , S(O)R 2a , S(O) 2 R 2a , C 3-8 cycloalkyl, and C 3-8 heterocycloalkyl having from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S;

alternatively, two R 2 groups on adjacent ring atoms are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 R 2c groups;

R 2a , R 2b and R 2c are each independently selected from the group consisting of hydrogen and C 1-6 alkyl;

each R 3a is independently halogen; and

subscript n is an integer from 0 to 3,

and salts thereof,

wherein said chemotherapeutic agent is an antimicrotubule agent.

9. The method of claim 8 , wherein the SGRM is:

10. The method of claim 8 , wherein the antimicrotubule agent is a taxane.

11. The method of claim 10 , wherein the antimicrotubule agent is selected from the group consisting of docetaxel, paclitaxel, nab-paclitaxel, docosahexaenoic acid bound-paclitaxel, polyglutamate bound-paclitaxel, paclitaxel-EC-1, ANG105, and glucose-conjugated paclitaxel.

12. The method of claim 8 , wherein the antimicrotubule agent is a vinca alkaloid.

13. The method of claim 8 , wherein the antimicrotubule agent is selected from the group consisting of vincristine, vinblastine, vindesine, vinorelbine and vinorelbine tartrate, and combinations thereof.

Assignments (1)

Continuity (6)

References Cited (200)

Cited By (1)

US 12,589,094